| Dr Ronald Fred Teitler, MD | |
|
70 East St, Holy Family Hospital Emergency Department, Methuen, MA 01844-4597 | |
| (978) 687-0156 | |
| (978) 794-9259 |
| Full Name | Dr Ronald Fred Teitler |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 70 East St, Methuen, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053322347 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 205875 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ronald Fred Teitler, MD 12 Maytum Way, Middleton, MA 01949-1618 Ph: () - | Dr Ronald Fred Teitler, MD 70 East St, Holy Family Hospital Emergency Department, Methuen, MA 01844-4597 Ph: (978) 687-0156 |
News Archive
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
Researchers in the Hereditary Endocrine Cancer Group of the Spanish National Cancer Research Centre - led by Alberto Cascón and Mercedes Robledo - have described the presence of mutations in the MDH2 gene, in a family with very rare neuroendocrine tumours associated with a high hereditary component: pheochromocytomas and paragangliomas that affect the suprarenal and parathyroid glands (groups of chromaffin cells in the central nervous system), respectively.
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above.
Purdue University researchers have found a method of identifying biological markers in small amounts of blood that they believe could be used to detect a myriad of diseases, infections and different medical conditions at early stages.
Standard guidelines for stroke treatment currently recommend clot removal only within six hours of stroke onset. But a milestone study with results published today in the New England Journal of Medicine shows that clot removal up to 24 hours after stroke led to significantly reduced disability for properly selected patients.
› Verified 3 days ago
Paul Allen Lockhart, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 East St, Methuen, MA 01844 Phone: 978-687-0156 | |
Steven G Crespo, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 East St, Holy Family Hospital, Emergency Department, Methuen, MA 01844 Phone: 978-687-0156 Fax: 978-688-0425 | |
Christopher Gruenberg, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 East St, Methuen, MA 01844 Phone: 978-687-0151 | |
Patrick Yegian, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 70 East St, Methuen, MA 01844 Phone: 781-820-9887 | |
Amanda Lieu, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 East St, Methuen, MA 01844 Phone: 978-687-0151 | |
Brian A Lisse, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: Holy Family Hospital Ed, 70 East Street, Methuen, MA 01844 Phone: 978-687-0156 |